ADXS: Positive Phase I/II Data Reported on ADXS-HPV
3/17/15We maintain our Outperform rating for ADXS and raise our target to $18.00 per share from previous $15.00 per share based on the recent clinical achievements.
Could This Clinical-Stage Biotech Stock Soar in April?
By Motley Fool, March 12, 2015, 08:59:01 AM EDT
Biotech to see continued growth in 2015: HC Wainwright
by Mourad Haroutunian
Both Advaxis (NASDAQ:ADXS) has benefited from this strong interest, the research firm said. In Deceber,Marque Investors Adage Capital Management and T. Rowe Price Associates invested nearly $17 million into Advaxis
3/5/15 Options Express
Cyber Security Market Forecast 2014-2015
LONDON/PRNewswire/ -- With attackers able to strike from anywhere and inflict damage on a significant(but often unnoticed) scale, the threat has never been greater. As a consequence, visigain has asessed that the value of the global Cyber Security market in 2014 will reach $76.68bn and will continueto grow Less
Common Sense,, PANW is $139 - CYBR Software Superior - CYBR Huge Upside
common sense peeps.